IMAP

I-Mab is a global clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel or highly differentiated biologics in oncology and autoimmune diseases. The company leverages its proprietary technology platforms, such as HySody for long-acting biologics and C-PRO for bispecific antibodies, to engineer next-generation therapies. Following a significant corporate restructuring in 2024, I-Mab divested its China-based operations to focus primarily on its U.S. and global clinical pipeline. Its lead assets include uliledlimab, a differentiated CD73 antibody, and givastomig, a bispecific antibody targeting Claudin 18.2 and 4-1BB. Headquartered in Rockville, Maryland, I-Mab maintains strategic partnerships with global pharmaceutical leaders like AbbVie and Roche to accelerate the development of its innovative portfolio.